{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"CR: complete disappearance of all enhancing abnormalities on contrast-enhanced cranial magnetic resonance imaging (MRI); no evidence of active ocular lymphoma as defined by absence of cells in the vitreous and resolution of any previously documented retinal or optic nerve infiltrates; negative cerebrospinal fluid (CSF) cytology; at the time of CR determination, participant had discontinued use of all corticosteroids for at least 2 weeks. CRu requires fulfillment of CR criteria but with these limitations: Fulfills CR criteria but had continued requirement for corticosteroid therapy at any dose; small but persistent enhancing abnormality on MRI related to biopsy or focal hemorrhage; persistent minor abnormality on follow-up ophthalmologic exam (related to persistent non-malignant cells in vitreous, or alterations in retina/optic nerve not consistent with tumor infiltration) if the abnormality is unlikely to represent ocular lymphoma.","groups":[{"description":"Participants received single doses of rituximab 750 mg/m\\^2 IV at Weeks 1 through 5, and 7, 9, 11, 14, 16, 18, 20, and 22; cytarabine 2 g/m\\^2 IV every 24 hours for 2 doses at Weeks 11 and 22; and single doses of MTX 8 g/m\\^2 IV at Weeks 3, 5, 7, 9, 14, 16, 18, and 20.","id":"OG000","title":"Rituximab, Cytarabine, and MTX"}],"populationDescription":"Due to early study termination, all efficacy data were documented by data listings only, no data analysis was performed.","reportingStatus":"POSTED","timeFrame":"Week 24","title":"Percentage of Participants With a Complete Response (CR) or Unconfirmed CR (CRu)","type":"PRIMARY"}